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Abstract 
Lavendamycin is a naturally occurring antibiotic isolated from Streptomyces 
lavendulae. Like its related antibiotic, streptonigrin, lavendamycin has anti-tumor, anti-
viral and anti-bacterial activity and is highly toxic in its natural form. Several recently 
synthesized lavendamycin analogs were found to have low toxicity and significant 
activity against HIV-reverse transcriptase. Initial studies have shown at least a few of the 
novel analogs have considerable anti-HIV-RT activity alone and also synergistic effects 
when used in combination with AZT. 
In this study, four lavendamycin analogs were assessed in vitro for their optimum 
HIV-RT inhibitory ratios and concentrations with AZT. While most of the analogs 
showed additive and synergistic activity with AZT, MB 72 and MB 344 exhibited 
significant synergistic activity in combination with AZT. When tested with AZT at a 
constant ratio of 1 :600, MB 344 was found to be the best candidate for drug therapy due 
to its very low toxicity, high inhibition ofHIV-RT alone and with AZT and good 
solublility in water. 
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Introduction 
Human Immunodeficiency Virus (HIV) has had a huge global impact on human 
health since its discovery in the early 1980's. Since then, scientists worldwide have 
focused on finding a cure or vaccine for this viral killer. For more than 20 years, HIV has 
led to over 20 million HIV -related deaths and continues to elude available drugs. With 
no end to the devastation in sight, the need for an effective treatment grows. 
The HIV virion is composed of three parts: the surface glycoprotein, the 
transmembrane glycoprotein and the central core. The two glycoproteins compose the 
outer spherical shell and aid in attachment to host cells. The central core contains two 
copies of the viral RNA genome and the viral enzymes protease, integrase and reverse 
transcriptase needed for viral replication. 
Reverse transcriptase (RT) is a RNA dependant DNA polymerase found only in 
retroviruses. RT is an essential part of the integration of the RNA genome into the host 
genome and its subsequent replication. R T has been an important target of current 
antiretroviral therapies including nucleoside and nonnucleoside RT inhibitors. These 
inhibitors such as AZT are commonly used in combination with one another due to HIV's 
development of resistance to monotherapy. In fact, because of the high replication rate, 
error prone nature and nonexistent editing function of reverse transcriptase, resistance to 
current combination therapies has also been found. The need for new reverse 
transcriptase inhibitors with low toxicity, significant inhibition, and high bioavailability is 
urgent. 
Lavendamycin, a highly toxic antibiotic with anti-viral, anti-bacterial and anti-
tumor activity was isolated from the bacterial species, Streptomyces lavenduale. Like its 
related antibiotic, lavendamycin was shown to possess anti-reverse transcriptase activity. 
Unfortunately, both antibiotics were too toxic to be used in vivo. Recently, Dr. 
Mohammad Behforouz of Ball State University devised a highly efficient method of 
producing new lavendamycin analogs with low toxicity and a variety of anti-viral 
capabilities. Several analogs were found to be inhibitory towards HIV-RT. 
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Previous studies have shown that many of these analogs not only inhibit HIV-RT 
in vitro but also act synergistically with AZT to produce significant inhibition of HIV-
RT. In this study, four analogs (MB 72, 76, 97 and 344) are analyzed in vitro for their 
inhibitory capabilities ofHIV-RT, both alone and with AZT. First each analog was 
tested using a checkerboard analysis with four concentrations of AZT (0.007, 0.01, 0.02, 
0.04IlM) and four concentrations of each analog (0.75, 1.5,3, 6IlM). Ifinhibitory 
potential was detected for a specific drug, the optimum ratio with AZT for synergistic 
inhibition was determined by computer analysis. The optimum ratio was then used for a 
constant ratio analysis in which increasing concentrations of both drugs at the same ratio 
were evaluated using the standard RT assay. The resulting data was again analyzed using 
the Calcsyn® program to give the best ratio and concentrations of the two drugs. 
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Review of Literature 
1. HIV characteristics 
The human immunodeficiency virus-l (HIV -1) has infected more than an 
estimated 57 million people and killed over 22 million individuals worldwide since the 
late 1970s. A majority of HI V-I infected individuals live in developing countries with 
little or no access to treatment. The highest rates of infection and mortality reside in parts 
of Asia and sub-Saharan Africa. There is currently no cure for HIV -1 and although 
treatments are available, they are too expensive for the developing countries where HIV-
1 rates are steadily increasing. The need for a vaccine or effective treatment has never 
been greater (2,3,5). 
HIV -1 belongs to the lentivirus family of retroviruses. Lentiviruses also infect a 
wide range of animal species, especially primates. HIV -1 is basically the same as other 
retroviruses except for six genes coding for regulatory and accessory proteins that add to 
the complexity of the HIV life cycle (5). This retroviral genome is encoded by a RNA 
molecule about 9-kb in length. The HIV -1 virus encodes a total of 15 proteins. Its 
genome encodes nine open reading frames, three of which encode the structural 
polyproteins gag, pol, and env. Gag is proteolyzed into four proteins that form the 
matrix, capsid, nucleocapsid and p6. The two env proteins, surface gp120 and 
transmembrane gp41, make up the outer envelope and the virion core. The three pol 
proteins, reverse transcriptase (RT), protease (PR), and integrase (IN), supply the 
enzymatic functions essential to the viral life cycle. The remaining frames encode six 
accessory proteins essential for viral replication. Tat and Rev add essential gene 
regulatory functions, while Vpu, Vif, and Vpr are important in viral assembly, 
disassembly, and down-regulation of CD4. The last protein, Nef, also aids Vpu in the 
down-regulation of CD4 (1,2,5). 
2. The HIV genome 
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As mentioned before, the three major genes of the HIV genome encode for the 
three structural proteins, which provide the outer membrane proteins and the core protein. 
The proteins encoded by these three genes, gag, pol, and env, are actually precursor 
molecules, which are further processed by viral protease to form smaller proteins that will 
actually provide the viral structure. The processed gag produces the matrix, capsid, 
nucleocapsid, and p6 core proteins. The matrix is the N-terminal piece ofthe gag 
polyprotein and lines the inner surface of the virion membrane of the mature viral 
particle. The matrix has other functions besides structure. Prior to assembly, the matrix 
targets the gag and gag-pol precursors to the plasma membrane. The matrix also appears 
to aid in the transformation of env gy1coproteins into viral particles. In addition, the 
matrix allows infection of non-dividing cell types like macrophages. The capsid forms 
the core ofthe virus particle. The N-terminal domain of the capsid protein is important 
for infectivity, which facilitates viral uncoating. The C-terminal domain assists in 
assembly through capsid dimerization and gag oligomerization. The nucleocapsid coats 
the genomic RNA and primarily binds to and delivers full-length viral RNAs to the 
assembling virion. It is believed that the coating ofthe genomic RNA is for compaction 
and protection from various nucleases. p6 is found at the C-terminal of gag and not only 
aids in viral particle release but also helps to incorporate Vpr during viral assembly (1). 
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The pol protein (polymerase) is also split into three enzymatic proteins: protease 
(PR), reverse transcriptase (RT), and integrase (IN). The protease is essential to the 
fonnation of mature, infectious virus particles. The protease cleaves various polyprotein 
sites, facilitating the fonnation of the matrix, capsid, nucleocapsid, p6, PR, RT, and IN 
final products. Reverse transcriptase is crucial to the life cycle of the virus because it 
transcribes a duplex DNA from the viral RNA, allowing for the integration and 
replication of the viral genome within the host cell, and also serves as a RNA nuclease. 
Integrase activity follows reverse transcriptase and catalyzes a series of reactions, thereby 
integrating the viral genome into the host cell's chromosome (1). 
The env gene codes for a fusion-incompetent precursor protein, gp 160, which is 
then proteolytic ally cleaved into two subunit viral surface proteins, gp41 and gp120. 
Both subunits are very important for the binding and fusion of the virus to the host cell. 
The surface glycoprotein (gp120) binds to cellular receptors, while the transmembrane 
glycoprotein (gp41) is involved in the fusion of the viral and cellular membranes after 
receptor binding (1,7). 
The remaining six genes code for six accessory proteins that playa smaller, but 
still very important role in the life cycle ofHIV. Vpr, vif, vpu, tat, rev, and nefhelp to 
increase the complexity ofthe virus. Viral protein r (vpr) is believed to play an important 
role in viral disassembly and transport of the pre-integration complex (PIC) to the host 
cell nucleus (2). Following entry and the uncoating of the virus, vpr transports the 
nucleoprotein complexes (PIC) to the host cell nucleus. These nucleoprotein complexes 
most likely consist ofRT, IN and the matrix; viral components needed for the next step, 
integration (1). Virion infectivity factor (vif) is either directly or indirectly involved in 
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virus assembly and is essential for viral replication in vivo and some cultured cell types. 
Vif is needed by HIV to establish infection in certain cell cultures such as H9 T cells, 
macrophages, and peripheral blood lymphoid cells. These cells are referred to as non-
permissive, while cell types that allow viral infection without vif are designated 
permissive (6). Viral protein u (vpu) down-regulates the expression of the cellular 
receptor, CD4, on the cell surface (2). In order to prevent newly synthesized gpl20 and 
gp41 from remaining in the endoplasmic reticulum through interactions with CD4 
molecules, vpu supports the degradation of CD4 in these complexes. The CD4 
degradation allows the env proteins to proceed to the cell surface and begin the assembly 
of viral particles. Vpu may also be involved in virion release (1). The transactivator of 
transcription (tat) is vital to viral replication because it influences the rate of transcription 
ofthe DNA form of the virus (provirus). Transcriptional initiation and elongation are 
mediated by RNA polymerase II, which is regulated by the HIV promoter located in the 
5' long terminal repeat (LTR). Tat is capable of enhancing transcriptional elongation and 
the processivity of transcribing polymerases through the interaction with this promoter. 
Tat also increases the production of viral mRNAs I DO-fold (1,5). The regulator of 
expression of viral proteins (rev) binds to a cis-acting RNA target, the Rev response 
element (RRE), found in all unspliced viral transcripts and targets them for nuclear 
export. Normally, unspliced cellular RNAs are either completely spliced or degraded in 
the nucleus (5). The last protein, negative factor (nej), reduces the level of cellular CD4 
with vpu. Nef assists in the transference of CD4 from the cell surface and golgi apparatus 
to lysosomes. This net-facilitated degradation ofCD4 once again prevents improper 
interactions of the CD4 with env proteins in the ER. Nefhas also been shown to down-
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regulate the expression ofMHC I molecules which may evade infected cells from 
detection and death by cytotoxic T cells (1). 
The nine gene viral genome is flanked by a 5' and 3' long terminal repeat (LTR) 
sequence. The 5' LTR contains the HIV promoter, a number of regulatory elements, and 
several sites for cellular transcription factors such as NF-KB, Spl, and TBP. 
Figure 1: Organization of the HIV -1 genome and virion (1) 
env 
3. HIV pathogenesis 
The major problem with HIV infection is that despite a strong humoral and cell-
mediated immune response, the immune system is only able to partially control the 
infection. There are actually two pathogenic forms of HIV -1, distinguished by their cell 
tropism. HIV-l strains that are primarily transmitted by sexual contact are called M-
tropic viruses. Also known as NSI (non-syncytium inducing) primary viruses, this form 
can infect and replicate in macrophages as well as primary CD4+ T cells. T -tropic 
viruses, also known as SI (syncytium inducing) primary viruses, are the HIV-l viruses 
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that only infect and replicate in helper T cells; both primary CD4+ T cells and established 
CD4+ T cells in vitro. M-tropic HIV-1 strains are found in about 90% of sexually 
transmitted HIV. Although T-tropic transmission is rare, once this strain becomes 
established they are more virulent and cause faster disease progression (22). 
The tropism of HIV -1 is dictated by the type of chemokine receptor used. CCR5 
is expressed on macrophages and therefore used by M-tropic viruses as their coreceptor. 
CXCR4 is expressed on T cells and is used as a coreceptor for T -tropic viruses. Primary 
T cells express both CCR5 and CXCR4 on their surface and are consequently infected by 
M-tropic, T-tropic, and dual-tropic viruses (7). Although HIV does need these 
coreceptors, CD4+ is still the major receptor for the virus. 
CD4+ T cells and CD8+ T cells are the principle cell types involved in the 
pathogenesis ofHIV. Since the CD4+ T cells are the primary targets for HIV, the 
depletion of these lymphocytes is considered to be the principle event responsible for the 
characteristic immune deficiency in HIV patients. CD8+ cytotoxic T lymphocytes are 
believed to play an important role in the control of HI V infection through their cytotoxic 
activity and the release of soluble factors to suppress viral replication. Unfortunately, 
CD8+ T cells are also thought to be susceptible to viral infection, which helps to explain 
why HIV has such a damaging effect on the immune system. Although not yet proven, in 
vitro experiments have shown that CD8+ T cells can become double-positive T cells 
(CD4+ICD8+) through stimulation by the T cell receptor complex. In other words, the 
infected CD4+ T cells cause the CD8+ cells to express the CD4+ antigen on their surface, 
consequently allowing CD8+ T cells to be infected and affected by HIV (9,10). The 
different types of coreceptors used and the different cell types that can be infected, allows 
HIV numerous ways to infect cells, avoid viral inhibitors, and deplete the immune 
system. 
4. Life cycle of HI V 
1) Virus entry 
12 
Viral entry into the host cell requires that the virus bind to a cell surface receptor, 
fuse with the cell, and then deliver a virion into the cytoplasm of the uninfected cell. The 
pathway of virus entry into a cell requires viral glycoproteins, coreceptors, and the cell 
surface molecule CD4. 
The proteolytic products of gp160, produced by the env gene, mainly facilitate 
viral membrane fusion. The surface subunit, gp120, remains noncovalently associated 
with the transmembrane subunit, gp41. gp 120 is responsible for binding the cell surface 
receptor, CD4. CD4 is a molecule commonly found on human T cells but can also be 
found on other cell types such as monocytes and macrophages (4,9). The joining of 
gp120 and CD4 is believed to activate the membrane fusion ability of gp41. However, 
the binding of CD4 is insufficient to activate membrane fusion. The fusion requires 
gp 120 to engage a second receptor following CD4 binding. This coreceptor can include 
any of the seven transmembrane-domain, G-protein-coupled receptors for chemokines. 
Chemokine receptors CCR5 and CXCR4 are believed to be the most common 
coreceptors for HIV -1 entry (4). Chemokine receptors normally function as cell surface 
proteins that bind small peptides called chemokines, which play an important role in host 
immune surveillance and inflammatory response. While the outer membrane portion 
binds the chemokine, the inner membrane portion is involved in cell signaling (3, 11). 
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After the conditions of specific pH and CD4 and coreceptor binding are met, membrane 
fusion may proceed. 
Figure 2: The replication cycle of HIV -1 (1) 
Membrane fusion is a complicated mechanism. Following the fusion-activating 
conditions, certain conformational changes occur allowing the fusion peptide component 
of gp41 to become unexposed. The fusion peptide release may be by the spring-loaded 
mechanism or just becomes uncovered through the movement of gp120. These 
movements result in the formation of the transient prehairpin intermediate. This 
intermediate spans two membranes: the viral transmembrane region and the host cell 
membrane where the fusion peptide is now located. The prehairpin intermediate then 
becomes a trimer of hairpins, facilitating membrane fusion (7). 
The completion of membrane fusion allows for the virus to infection the host cell. 
Successful infection requires that the nucleoprotein core, consisting of the viral genome 
and proteins, be delivered into the cytoplasm. This nucleoprotein core contains all the 
components necessary for the continuation of the HIV life cycle through further 
production of new virions. 
2) Reverse transcriptase 
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In order for the virus to be replicated by the host cell it must be integrated into the 
host chromosome. Before viral integration can occur, the viral RNA genome must be 
transcribed into duplex DNA. The viral enzyme, reverse transcriptase, catalyzes this 
conversion from genomic RNA to a double-stranded proviral DNA copy. This change 
occurs through the actions of three components: DNA-dependant DNA polymerase, 
RNA-dependant DNA polymerase, and ribonuclease H (RNase H). All three elements 
are provided by the enzymatic activities of reverse transcriptase. Reverse transcription of 
the viral RNA begins at the 3' end of a tRNA-Lys primer annealed to the primer binding 
site in the 5' region ofthe genomic RNA. Although RT can use other tRNAs, reverse 
transcription is most effective with tRNA-Lys. After the tRNA initiation, reverse 
transcription involves two DNA strand transfer reactions in which RNA-dependant DNA 
polymerase creates a DNA strand from the viral RNA template, followed by the use of 
DNA-dependant DNA polymerase to produce the complementary DNA strand. The 
RNase H component ofRT facilitates the cleavage of the RNA portion of the RNA-DNA 
hybrid so that the plus and minus DNA strand may join to form the DNA duplex (1,12). 
Reverse transcriptase is an asymmetric heterodimer consisting of p5l and p66 
polypeptides originating from the pol protein. Both p5l and p66 subunits contain a 
polymerase domain composed of four subdomains: fingers, palm, thumb, and 
connection. In addition, the p66 subunit contains the RNase H domain. Although the 
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subdomains of both subunits are identical in sequence of amino acids, the polymerase 
subdomains of the subunits are oriented differently forming a large active site cleft in p66 
and an inactive, closed structure for pSI. Reverse transcriptase has also been found to 
undergo large conformational rearrangements, especially changing the position of the p66 
thumb, upon nucleic acid binding. These conformational changes of the RT molecule 
may be important in moving RT along the nucleic acid chain or to correctly position 
RNase H when needed (1,12). 
Figure 3: Structure ofHIV-RT (12) 
The reverse transcriptase molecule is believed to be an ideal target for drug 
therapy. Two types ofRT inhibitors have already been developed. Nucleoside analog 
inhibitors, such as AZT, bind to the polymerase active site, interrupting chain elongation. 
Non-nucleoside inhibitors, such as nevirapine, bind to a hydrophobic pocket near the 
polymerase active site, causing allosteric changes that inactivate RT. Unfortunately, the 
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binding of these two drug types is very specific so resistance can be conferred by as little 
as one amino acid change (1,12,15). 
3) Viral integration 
After reverse transcription has produced the duplex DNA, viral integrase 
recognizes the LTR sequences and catalyzes three reactions that insert the DNA 
precursor into the host genome. The viral DNA precursor contains a complete plus 
strand and a discontinuous minus strand that is probably completed by host enzymes after 
integration. In the first step, integrase removes two nuc1eotides from the 3' end of each 
viral DNA strand, leaving projecting cytosine-adenine-OH ends. The second step 
involves the 3' ends being joined covalently to the 5' ends of the host DNA. In the third 
step, unpaired nuc1eotides at the viral 5' ends are removed and the ends are joined to the 
3' host DNA ends. The final result is an inserted provirus with five base-pair 
duplications of the target site DNA on each side (1,8). 
Integration can have many target sites within the host genome. In vitro studies 
have shown that viral integration may have a preference for sites of kinked or distorted 
DNA, common to nuc1eosomes. It has also been found that at least two host cell 
proteins, HMG-I(y) and BAF, increase the efficiency of integration (1,8). 
·4) Viral protein expression 
The expression and production ofthe viral proteins from the newly integrated 
provirus requires the use of the host cell's protein production mechanisms and the virus' 
regulatory proteins tat and rev. Host transcription of the viral DNA produces spliced 
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viral mRNAs, which produce all nine viral polyproteins following host translation of the 
viral mRNA (1). 
Viral protein expression begins by viral transcripts being expressed from the 
promoter in the 5' LTR. Tat regulates and greatly increases the rate of transcription. 
While cellular RNA polymerase II and transcription factors such as NF-KB, Spl, and 
TBP oversee the initiation of transcription, tat is required for elongation to proceed. In 
its absence, polymerase does not transcribe more than a few hundred nucleotides. Tat has 
a common transcriptional activator structure, including an activation domain and a RNA 
binding domain. In order for tat to function correctly, a tat-activation region (TAR) must 
be present in the form of a bulged, RNA stem-loop structure found at the 5' end of the 
viral mRNA. Following cellular (RNA polymerase II and transcription factors) initiation 
of transcription, tat complexes with cellular CycT and Cdk9 and then binds to the TAR 
on the small mRNA transcript. The Cdk9 then hyperphosphorylates a component of the 
RNA complex, allowing elongation to proceed (1,5). 
Rev facilitates the exportation ofthe transcribed viral mRNA from the nucleus to 
the cytoplasm, where it can then be translated. Rev binds to a cis-acting RNA target, rev 
response element (RRE), present in all unspliced viral transcripts through its NH2 
domain. After binding, rev-rev multimerization occurs, forming a complex that acts as a 
nuclear exportation signal. Once in the cytoplasm, the associated cellular exportation 
proteins disassociate and rev returns to the nucleus, leaving the viral mRNA to be 
translated (5). Viral mRNAs are then translated in the cytoplasm, producing gag and gag-
pol polyproteins. Env mRNA is translated at the endoplasmic reticulum. The translation 
ofne/is an important event because it down-regulates the surface expression ofCD4, 
allowing the gag and gag-pol polyproteins to localize on the cell membrane and 
preventing CD4 from interfering with the newly synthesized env proteins (1). 
5) Virus assembly and budding 
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The matrix is responsible for the localization of the gag and gag-pol polyproteins 
to the plasma membrane before virus assembly. The matrix consists of two main parts: 
basic residues and an N-terminal myristate group. The matrix forms a trimeric structure, 
believed to be responsible for virus assembly. When matrix residues responsible for 
trimerization have been mutated the ability to assemble has been lost. Other residues are 
also important for membrane localization. The nucleocapsid, like the matrix, also comes 
from the gag polyprotein. The main function of the nucleocapsid during assembly is to 
bind to the packaging signal and deliver viral RNAs to the assembling virion (1). 
Budding of the viral particle begins once the core particle has been assembled 
from the gag and gag-pol polyproteins, vif, vpr, nef, and genomic RNA. After the 
assembly of the core particle, the gag and gag-pol polyproteins are further processed into 
the matrix, nucleocapsid, capsid, p6, protease, RT, and integrase. Before the budding 
particle can leave the cell surface as a mature virion, it must first be coated by the surface 
and transmembrane proteins. These proteins are products of the env polyprotein, which 
is initially complexed with CD4 in the endoplasmic reticulum. Vpu then promotes CD4 
degradation, releasing env and transporting it to the cell surface. The cell surface CD4 
must then be degraded by nef at the site of viral budding so that the surface and 
transmembrane proteins may coat the budding virus. Once coated, the virus particle is 
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released from the host cell and undergoes the process of maturation. Viral maturation is 
accomplished through protease cleaving the gag and gag-pol polyproteins and vif 
ensuring intracellular and endogenous reverse transcription and correct viral stability and 
morphology. Once the virion is mature it is ready to infect another host cell, completing 
the life cycle ofHIV (1,6). 
5. Reverse Transcriptase Inhibitors 
The reverse transcription enzyme is unique to retroviruses. It is also very 
important to these type of viruses because it facilitates the production of a DNA copy of 
the viral RNA genome that can be inserted into the host cell DNA for viral replication. 
The uniqueness and importance of reverse transcriptase make it an excellent target for 
anti-viral drugs. Currently, RT inhibitors can be divided into two classes, nucleoside and 
non-nucleoside inhibitors. 
1) Nucleoside inhibitors 
Nucleoside inhibitors (NRTIs) were the first to be discovered, before the structure 
ofRT had even been determined. These inhibitors terminate chain elongation through 
the nucleoside analog substrates blocking in the substrate-binding site. Currently 
approved nucleoside inhibitors include zidovudine (AZT), didanosine (ddI), lamivudine 
(3TC), stuvudine (d4T), zalcitabine (ddC), and abacavir (ABC) (14,13,15,18,21). 
In the case of AZT, its 3'-azido group prevents the formation ofa 3'-5' 
phosphodiester bond, terminating the viral DNA chain. AZT was produced in 1987 as 
the first generally available AIDS drug. The popular drug is administered orally and has 
a high bioavailability and short intracellular half-life. Didanosine is an analog of inosine 
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and like AZT, its active form is a triphosphate created by cellular enzymes. It also has a 
longer half-life than AZT, allowing for only once a day dosing. Zalcitabine is related to 
didanosine and is active against HIV at very low concentrations. Unfortunately, it has a 
very short half-life, so multiple doses are required per day. Stavudine is a modification 
of thymidine that is well tolerated with few side effects in patients (14). 
4) Non-nucleoside inhibitors 
While nucleoside inhibitors were developed to interfere with the mechanism of 
RT, non-nucleoside inhibitors generally interfere with the structure of the enzyme. Non-
nucleoside inhibitors (NNRTls) are chemically diverse, hydrophobic compounds that 
comprise over 30 different classes. Unlike NRTIs, non-nucleoside inhibitors do not 
require intracellular metabolism for activity and frequently inhibit only HIV -1. They are 
characterized by their noncompetitive inhibition ofRT activity and are primarily low or 
noncytotoxic. NNRTIs inhibit reverse transcriptase activity by binding to a hydrophobic 
pouch close to the p66 active site. The binding subsequently causes allosteric changes 
that prevent reverse transcription of the viral RNA genome. There are currently three 
non-nucleoside inhibitors approved for use against HIV: nevirapinne, delavirdine, and 
efavirenz (12,13,14,15,18,21). 
Navirapine was the first NNRTI to gain approval. The drug has a high 
bioavailability in its oral form and is able to induce its own metabolism. Delaviridine has 
a short half-life and requires many doses a day. Efavirenz is very effective when used in 
combination therapy, but resistance to it is easily gained when used alone (14). 
6. Protease inhibitors 
Another group of approved drugs inhibit the viral enzyme protease. Protease is 
required for proper virion assembly and maturation. Inhibition of protease leads to the 
production of immature, noninfectious virus particles. There are currently six protease 
inhibitors approved for use: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, and 
lopinavir. The availability of protease inhibitors has changed the course of the disease 
and considerably reduced HIV's morbidity and mortality (14,21). 
7. Combination therapy 
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Although many inhibiting drugs have been developed, mutant HIV strains 
resistant to all of them have been identified. The development of resistance is due to both 
the high replication rate of the virus and the error prone nature of HI V RT, leading to 
mutation. Individuals infected with HIV produce over 1 billion virions a day. The HIV 
RT has no editing function and therefore makes an error for every 2,000-5,000 
nucleotides that are polymerized. It is not surprising then that any of the current drugs 
used as monotherapy only offer a short-term benefit. Resistance developed through 
mutation is often observed only a week or two after the start of therapy. Current HIV and 
AIDS treatment now relies on combination therapy, using nucleoside inhibitors with non-
nucleoside inhibitors or protease inhibitors. Combinations of retroviral drugs have shown 
a dramatic reduction of AIDS-related morbidity and mortality. Combination therapy of 
RT and protease inhibitors has effectively suppressed viral replication to minute levels 
for long periods of time and decreases the ability of viruses to mutate to resistance to 
several drugs at once. NNRTIs are especially easy to gain resistance against. Since their 
binding site is very specific, a single amino acid change in that site can render the drug 
useless. Therefore, NNRTIs must be used in combination therapy with other drugs that 
together prevent the emergence of HIV strains resistant to NNR TIs (13,14,16,17,18). 
Proper combination strategies are selected by their ability to show synergy, while at the 
same time, maintaining low toxicity (21). 
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In combination therapy, synergy is defined as yielding an amount of inhibition 
activity above the level of additive interaction. In other words, the amount of inhibition 
of two drugs together is greater than the sum of the amount of inhibition of each drug 
alone. NNRTIs commonly exhibit synergistic inhibition ofHIV when used in 
combination with NRTIs (16,20,21). 
7. Lavendamycin 
Lavendamycin is an antibiotic produced by Streptomyces that has shown 
considerable biological activity and anti-tumor capabilities. Furthermore, lavendamycin 
and another Streptomyces antibiotic, streptonigrin, have been shown to contain strong 
anti-reverse transcriptase activity against HIV-RT. Regrettably, these antibiotics are 
highly toxic to the human body, thought to be due to disruption of DNA synthesis. 
Recently, M. Behforouz of Ball State University has synthesized several novel 
lavendamycin analogs using short, efficient synthetic methods that produce high product 
yields (24,25). These analogs have so far been shown to have significant anti-reverse 
transcriptase activity, possible synergistic activity, and low cellular and animal 
cytotoxicity (26). 
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8. Purpose of this study 
As of2000, it is estimated that 30-50% of HI VIA IDS patients are failing 
combination therapy due to the development of resistance and noncompliance with 
dosing schedules. The development of new HIV inhibitors, with low side effects and 
high bioavailability, are greatly needed to provide more combination therapy options and 
to keep the upper hand on the battle with HIV (18). The purpose of this study is to 
further evaluate novellavendamycin analogs in combination with AZT for their 
synergistic inhibition ofHIV-RT in vitro. The inhibition activity of these analogs will be 
determined though the use of four concentrations of AZT (0.04, 0.02, 0.01, and 
0.007f..lM) in combination with four concentrations oflavendamycin analogs (MB) (6,3, 
1.5, and 0.75f..lM). The various combinations ofthe two drugs will be tested through a 
checkerboard analysis and the resulting data will be analyzed for signs of synergistic, 
additive, or antagonistic activity using the Ca1cusyn® computer program (29). Promising 
drug combinations will then be tested using the optimum synergistic ratio of the two 
drugs at decreasing and increasing concentrations. This study will hopefully reveal 
several MB analogs as potential non-nucleoside reverse transcription inhibitors to be 
further tested for their possible use in anti-HIV combination therapy. 
Materials and Methods 
1. Detennination of Anti-HIV Reverse Transcriptase Activity 
1) Assay reagents 
a) 8X reaction buffer- 800mM Tris HCL, 40mM MgC12, 480mM NaCl, and 
40mM of dithiothreitol, at a pH of 8.0. 
b) Poly (rA)-oligo (dT)- purchased from Amersham Phannacia Biotech, 
Piscatway, NJ (25units/1366Jlg) and diluted into 34.15 ml of buffer (O.OIM 
Tris HCl, O.IM NaCl at pH 7.5) to give a 40Jlg/ml stock solution, which was 
stored at -80°C. A final concentration of 4 Jlg/ml would result in the reaction 
mixture. 
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c) [MethyPH]-deoxythymidine 5 '-triphosphate (3[H] TTP)- purchased from lCN 
Biomedicals, Costa Mesa, CA (lmCi/ml). 
d) Wash solutions- 1) 5% trichloroacetic acid in O.OIM sodium phosphate 
monobasic, 2) 0.6M sodium chloride in 0.06M sodium citrate, 3) double 
distilled, deionized water, and 4) 95% ethanol. 
e) Scintillation fluid, type E- purchased from Sigma Chemical Company, St. 
Louis, MO. 
2) Drugs 
a) AZT Triphosphate- purchased from Moravek Biochemical, Brea, CA (5JlM in 
Iml). 
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b) Lavendamycin analogs- obtained from Dr. Mohammed Behforouz, Ball State 
University Chemistry Department (Table 1). Each analog, except MB 344, 
was dissolved in dimethyl sulfoxide (DMSO) to a concentration of 1/lg/ml. 
MB 344 was dissolved in RPMI-1640 culture media with 5mM Hepes buffer 
to a concentration of 1/lg/ml. Each analog stock solution was diluted with 
double distilled water to 15,6,3, 1.5, and 0.75/lM for use in the final reaction 
mixture. 
3) HIV Reverse Transcriptase Enzyme 
a) Recombinant HIV-RT from E.coli plasmid, pRC-RT (500units/vial)-
purchased from Worthington Biochemical Corp., Frenhold, NJ, ali quoted to 
150units/ml, and stored at -80°C. 
b) HIV-RT storage solution- 100rnM potassium phosphate buffer (33mM 
KH2P04, 67mM K2HP04 3H20) at pH 7.1, ImM dithiothreitol (DTT), and 
10% glycerol at pH 7.1. 
4) Anti-HIV-RT Activity Assay 
The inhibition ofHIV-RT activity was measured by a modification of Take and 
Okada et.al and Robins et.al (27,28). 
The assay was performed as follows: The lavendamycin analogs were dissolved 
in DMSO at a concentration of l/lg/ml, sometimes with sonification and mild heat, and 
then were serially diluted with double distilled water to achieve concentrations ranging 
from 15 to 0.75/lM. For each assay, the final reaction mixture containing 8X buffer, 
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ddH20, 3[H]TTP, template primer, and HIV-RT was premixed in a 15ml sterile tube in 
the required amounts for each experiment. The tube was then mixed by vortexing and 
placed on ice. The inhibitors, MB analogs or AZT, were added to the appropriate wells 
in a 24 well microtiter plate and ddH20 was added to each well to bring the total volume 
in all wells to 103/ll. 195/l1 of the final reaction mixture was then added to each ofthe 
wells and the plate was gently mixed. The plate also included triplicate sets of three 
wells, each with no inhibitors, to serve as enzyme controls. The plate was then incubated 
for one hour at 37°C. Following incubation the reaction was stopped by the addition of 
O.1M EDTA. Each well was then mixed by pipeting and 15ul from each well was placed 
on a lcm square of What man DE81 ion exchange paper. Three squares were each soaked 
with the 15ul solution for each well. After drying, each filter paper was washed for 8 
minutes three times with 5% TCA-NaHP04 12 H20, three times with O.6M NaCI-
O.06mM Na Citrate, 1 time with double distilled water, and 1 time with 95% ethanol. 
Each 8-minute wash consisted of a vial containing the filter papers for each well and 4-5 
ml wash solution, being shaken by a shaker. After each wash, the wash solution was 
removed by vacuum. After drying, each filter paper was placed in a fresh, separate vial 
with 5ml of scintillation fluid - type E. The amount of 3[H]_ TTP uptake (noting 
successful HIV -R T synthesis) was measured as counts per minute on a Beckman liquid 
scintillation counter. Each experiment for a particular MB analog was repeated at least 
twice to verify results. 
Figure 4: Assay Procedure 
-For each triplicate 298~1 Reaction Mixture: 8X buffer. ......... 39.2~1 
-Incubate at 37°C for one hour 
-Add EDTA to stop reaction 
DdH20 ............ 121.8~1 
3[H]_ TTP .......... .2~1 
Template primer..30~1 
HIV-RT ............ 2~1 
AZT and/or 
MB analogs ........ Various depending on 
concentration 
-Add 15~l from each well to lcm square filter paper (in triplicates for each well) 
-Wash filter papers for 8 minutes for each washing solution 
-Let filter paper air dry 
-Add filter paper to 5ml scintillation fluid 
-Count 3[H]-TTP uptake using scintillation counter 
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TABLE 2 
Lavendamycin Analogs 
R1NH 
R2 
o 
R3 
COMPOUND R1 R2 R3 
Lavendamycin NH2 C02H CH3 
MB-21 CH3CO C02CH3 CH3 
MB-61 CH3CO C02H H 
MB-72 CH3CH2CH2CO C02CH2CH2CH2CH3 H 
MB-76 CH3CO CONH2 H 
MB-S3 H C02CaH17-n H 
MB-97 H CONH2 H 
MB-344 CH3CO CONHCH2CH2OPO(OH)2 H 
--, It, 
Results 
1. Combined effect oflavendamycin analogs and AZT on HIV-RT 
Today's treatment of HI V is dependant on combined drug therapies using ideal 
anti-reverse transcriptase drugs. An ideal drug must significantly inhibit reverse 
transcriptase at a concentration low enough to be non-toxic. There are three drug 
interactions possible when multiple drug therapy is concerned: an anatagonistic, 
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additive, or synergistic effect. In an antagonistic interaction, the drugs interfere with each 
other to produce a total effect that is significantly lower than the additive effects of each 
drug alone. In an additive interaction, the drugs act independently of each other to 
produce a total effect that is about equal to the additive effect of each drug alone. 
Synergistic interaction is ideal for the use of multiple drugs because the drugs combine to 
give a total effect that is higher than the additive effects of each drug action alone. 
Synergism allows for high inhibition of reverse transcriptase while also maintaining low 
drug concentrations. 
First, the combined effect ofthe lavendamycin analogs with AZT -triphosphate 
was analyzed using a checkerboard method with a range of concentrations of both drugs. 
The results ofthis assessment are presented in Table 3 and show two separate trials for 
MB 97 and MB 344, and one trial for MB 72 and MB 76. MB 72 and MB 76 were done 
only once as a follow up on previous work. The results were then analyzed using the 
method of Chou and Talalay and characterized by the combination indices (CI) for each 
two drug combination (29). The combination index is derived from a computerized 
calculation ofthe slope of the median-effect plot and the x-intercept of the plot. These 
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graphs of the data give the dose-effect curve and the potency of each drug, both alone and 
in combination, respectively. A sample median-effect plot and dose-effect curve for the 
MB 344 and AZT -triphosphate combination is shown in Figure 4. 
The results of the checkerboard analysis show that combinations of all the analogs 
with AZT -triphosphate exhibit synergistic effects, along with additive and antagonistic 
effects. The greatest amount of synergism among different concentrations was detected 
in the analogs MB 344 and MB72. 
MB 344 and MB 72 were further analyzed to find the dose reduction index ofthe 
drug combinations. Once again the method of Chou and Talalay was used to find the 
dose-effect curves for each drug as well as for their combination with AZT -triphosphate 
at constant-ratios. The constant ratio analysis allowed for the determination of the 
combination indices (CI) at a 50% and 75% effect level and the dose reduction index 
(DRI) at 50% inhibition for both MB 344 and MB 72, shown in Table 4. The DRI is a 
measure of how much each drug can be reduced in a synergistic combination and still 
give a desired inhibition. As seen in the checkerboard analysis, MB 344 displayed the 
best results in the constant ratio analysis (1 :600 ratio) with very strong synergism 
(CI<O.l) for both the 50% and 75% effect levels and a DRI of more than 100 times for 
both the analog and AZT -triphosphate at 50% inhibition. 
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Table 3. Combination Indices Determined for Lavendamycin Analogs Performed by Checkerboard Analysis 
Lavendamycin Analogs (JlM)a 
72 76 97 344 
0.75 1.5 3 6 0.75 1.5 3 6 0.75 1.5 3 6 0.75 1.5 3 6 
Trial 1 0.54 0.62 0.65 0.44 1.16 1.08 1.07 1.14 0.49 0.49 0.41 0.41 0.68 0.81 0.80 0.64 
0.007 
Trial 2 ND ND ND ND ND ND ND ND 0.70 0.87 1.04 1.12 0.48 0.49 0.49 0.32 
AZT (,..M) 
Trial 1 1.03 0.90 0.64 0.56 1.28 0.96 1.07 0.98 0.54 0.69 0.59 0.37 1.05 0.75 0.69 0.56 
0.01 
Trial 2 ND ND ND ND ND ND ND ND 1.24 1.17 1.19 0.77 0.75 0.69 0.28 0.28 
aFour different lavendamycin analogs were combined in different ratios with AZT-triphosphate and added to HIV-RT enzyme assays in triplicate. Two separate trials were performed for 
each drug unless otherwise noted "not done" (ND). The combination index (CI) of each drug combination was analyzed by the method of Chou and Talay (29). CI values <1 indicate 
synergism, 1 indicates additive effects and> 1 indicates antagonism. CI values <0.7 are considered to be synergistic and are shown in bold. Values ~0.71 and :5:0.9 are considered to be 
moderately or slightly synergistic and are shown in italics. 
Table 4. Two Drug Combination of AZT and lavendamycin analogs at constant molar ratios 
72 
344 
Molar 
Ratio 
AZT:MB 
1:600 
1:857 
1:600 
1:857 
CI at HIV-RT Inhibition of: 1 
50% 75% 
0.45 ± 0.06 0.29 ± 0.09 
0.39 ± 0.06 0.31 ± 0.11 
<0.1 ± 2.24 <0.1 ± 0.66 
2.17 ± 3.68 1.02 ± 0.67 
Dose Reduction2 Index 
50% 
AZT MB 
3.0 8.2 
3.9 7.4 
>100 >100 
>40 0.47 
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ICombination index at the effect level of 50% and 75% as calculated by the method of Chou and 
Talay. Additive effect (CI=l), synergism (CI<l), or antagonism (CI> 1) (29). 
2Dose Reduction Index is a measure of how much the dose of each drug in a synergistic 
combination may be resuced at the 50% effect level compared with the doses of each drug alone 
(30). 
Figure 4. Example of median-effect and dose-effect plots for MB 344 
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---. 
• 
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33 
Discussion 
Combination therapy is now essential for the treatment of patients afflicted with 
HIV. As HIV is now becoming resistant to current combinations of drugs, the need for 
novel medicines has never been so great. Unfortunately, rapid viral mutation, drug 
toxicity, large drug doses and patient non-compliance make it hard to develop new 
treatments. The ideal drug would be highly potent and synergistic with other drugs, 
easily produced, have a low toxicity and be required in small doses. 
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Lavendamycin analogs were initially tested because of their relatedness to 
streptonigrin, a reverse transcriptase inhibiting but highly toxic antibiotic. Lavendamycin 
is also toxic but the novel analogs produced by Dr. Mohammad Behforouz have exhibited 
low toxicity in both murine and human cells. Previous studies have shown that for 
lavendamycin analogs, the mean inhibitory concentration required to inhibit 50% ofHIV-
RT (IC50) is well below the mean concentration required to kill 50% of human and 
murine cells (CC50). The IC50 for MB 72 and MB 76 was much less than the CC50 of 
the drugs on human and murine cells. MB 344 had an IC50 even lower than its CC50. 
However, MB 97 was found to have an IC50 much greater than its CC50 for both cell 
types, so it was too toxic to actually be considered for drug use (21). Therefore, MB 344, 
72 and 76 could be used in human HIV drug therapy if found to be potent enough. 
The four lavendamycin analogs were chosen based on their performance in 
previous studies of both synergistic inhibition of HI V -RT and cellular cytotoxicity. 
Although all four analogs that were tested showed synergistic capabilities, only the most 
promising analog should be further tested due to HIV's devastating capabilities. MB 76 
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showed barely any synergistic potential, while MB 97 did not work well in experimental 
tests and is highly toxic. Although MB 72 did exhibit good synergistic activity, MB 344 
is clearly the best candidate with its high synergism at 50% and 75% effect levels and 
drastic DRI at the 1 :600 molar ratio with AZT -triphosphate. MB 344 also showed to 
have an IC50 value almost 10 times less than human and murine CC50 values (21). MB 
344 was also found to solubilize in water much better than most other analogs, which 
could possibly explain its effectiveness and make drug production easier. 
In summary, testing has shown that at least one of the new lavendamycin analogs, 
MB 344, has characteristics of a promising new drug. The water-soluble drug has 
exhibited great inhibitory activity alone and in combination and very low toxicity in 
animals. This potential candidate may prove to be a potent addition to the nonnucleoside 
reverse transcriptase inhibiting HIV drugs, following further testing. 
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